Hostname: page-component-76d6cb85b7-8p85h Total loading time: 0 Render date: 2026-07-21T17:54:26.636Z Has data issue: false hasContentIssue false

Adjunctive Intraarterial Thrombolysis after Thrombectomy in Large Vessel Occlusion Stroke: A Meta-Analysis of RCTs

Published online by Cambridge University Press:  15 July 2025

Mohammed A. Almekhlafi
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Community Health Sciences and O’Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Hyungjong Park*
Affiliation:
Department of Neurology, Keimyung University, School of Medicine, Daegu, South Korea.
Nishita Singh
Affiliation:
Department of Internal Medicine (Neurology Section), Rady Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
Ronda Lun
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Umberto Pensato
Affiliation:
Department of Neurology, IRCCS, Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy
Katrina Hannah Dizon Ignacio
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Community Health Sciences and O’Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada
Johanna M. Ospel
Affiliation:
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Aravind Ganesh
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Community Health Sciences and O’Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Hotchkiss Brain Institute, Calgary, AB, Canada
Mohamed Alshamrani
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, Rydiah, Saudi Arabia
Andrew M. Demchuk
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Hotchkiss Brain Institute, Calgary, AB, Canada
Michael D. Hill
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Hotchkiss Brain Institute, Calgary, AB, Canada Department of Internal Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Bijoy K. Menon
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Department of Community Health Sciences and O’Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Hotchkiss Brain Institute, Calgary, AB, Canada
*
Corresponding author: Hyungjong Park; Email: hjpark209042@gmail.com

Abstract

Background and purpose:

Adjunctive intraarterial (IA) thrombolysis after endovascular thrombectomy may improve clinical outcomes in patients with large vessel occlusion (LVO) stroke possibly due to improvement in microvascular reperfusion.

Methods:

We conducted a meta-analysis of randomized controlled trials (RCTs) evaluating IA thrombolysis with tenecteplase, alteplase or urokinase in anterior or posterior circulation LVO stroke after successful reperfusion (modified Thrombolysis in Cerebral Infarction 2b–3). Efficacy outcomes were excellent functional outcome (modified Rankin Scale [mRS] 0–1), functional independence (mRS 0–2) and recovery without any disability (mRS 0) at 90 days. Safety outcomes included symptomatic intracerebral hemorrhage (ICH), any ICH and death. Odds ratios (OR) and 95% confidence intervals (CI) were pooled using random-effects models.

Results:

Seven RCTs (n = 2,130; 2022–2025) were included. IA thrombolytic drugs used were alteplase, tenecteplase and urokinase with doses ranging from 10 % to 50% of recommended IV dosage. IA thrombolysis significantly improved excellent functional outcome (mRS 0–1: OR 1.45, 95% CI 1.19–1.76) and recovery without any disability (mRS 0: OR 1.34, 95% CI 1.09–1.64), without safety risks (symptomatic ICH: 5.05% with IA thrombolytics vs. 4.49% in standard). Paradoxically, there was no difference in functional independence (mRS 0–2) (OR 1.09, 95% CI 0.99–1.20). Additionally, tenecteplase or alteplase at doses equivalent to 25% or 50% of recommended IV dosage significantly improved excellent functional outcome.

Conclusions:

IA thrombolysis offered immediately following EVT with successful reperfusion improved excellent functional outcome and recovery without disability at 90 days with an acceptable safety profile.

Résumé

RÉSUMÉ

Thrombolyse intra-artérielle adjuvante après une thrombectomie dans le cas d’un AVC avec occlusion des gros vaisseaux : une méta-analyse portant sur des essais contrôlés randomisés

Contexte et objectif :

La thrombolyse intra-artérielle adjuvante (TIAA) après la thrombectomie endovasculaire (TEV) peut améliorer l’évolution de l’état de santé clinique des patients victimes d’un AVC avec occlusion des gros vaisseaux, et ce, probablement en raison de l’amélioration de la reperfusion microvasculaire.

Méthodes :

Nous avons effectué une méta-analyse des essais contrôlés randomisés (ECR) évaluant la TIAA avec le tenécteplase, l’altéplase ou l’urokinase dans le cas d’un AVC avec occlusion des gros vaisseaux de la circulation antérieure ou postérieure après une reperfusion réussie (thrombolyse dans l’infarctus cérébral 2b-3 modifiée). Les critères d’efficacité étaient un excellent résultat fonctionnel (échelle de Rankin modifiée [ERM] : 0-1), l’autonomie fonctionnelle (ERM : 0-2) et la récupération sans aucune invalidité (ERM : 0) au bout de 90 jours. Les critères de sécurité comprenaient l’hémorragie intracérébrale (HIC) symptomatique, toute présence d’HIC et le décès. Les rapports de cotes (RC) et les intervalles de confiance (IC) à 95 % ont été regroupés à l’aide de modèles à effets aléatoires.

Résultats :

Au total, sept ECR (n = 2 130 de 2022 à 2025) ont été inclus. Les médicaments thrombolytiques intra-artériels utilisés étaient l’altéplase, la tenécteplase et l’urokinase, avec des doses allant de 10 à 50 % de la dose intra-artérielle recommandée. En définitive, la TIAA a amélioré de façon notable la fréquence d’excellents résultats fonctionnels (ERM : 0-1 ; RC : 1,45 ; IC 95 % : 1,19-1,76) et la récupération sans aucune invalidité (ERM : 0 ; RC : 1,34 ; IC 95 % : 1,09-1,64), et ce, sans risque pour la sécurité (HIC symptomatique : 5,05 % avec les médicaments thrombolytiques intra-artériels contre 4,49 % en ce qui regarde la norme). Paradoxalement, il n’y avait pas de différence en termes d’autonomie fonctionnelle (ERM : 0-2 ; RC : 1,09 ; IC 95 % : 0,99-1,20). De plus, le tenécteplase ou l’altéplase à des doses équivalentes à 25 % ou 50 % de la dose intra-artérielle recommandée ont significativement amélioré la fréquence d’excellents résultats fonctionnels.

Conclusions :

La TIAA proposée immédiatement après une TEV avec reperfusion réussie a amélioré la fréquence d’excellents résultats fonctionnels et la récupération sans invalidité au bout de 90 jours tout en maintenant un profil de sécurité acceptable.

Information

Type
Original Article
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Supplementary material: File

Almekhlafi et al. supplementary material

Almekhlafi et al. supplementary material
Download Almekhlafi et al. supplementary material(File)
File 10.5 MB